Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PARP Inhibitors Pave Way for Personalized Care in CRPC

April 30th 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

Increased Somatically Acquired Alterations May Lead to More Aggressive Prostate Cancer, Mortality in Black Patients

April 29th 2021

A higher incidence of somatically acquired genetic alterations, including damaging mutations in ZMYM3 leading to genomic instability, as well as deletions in MAP3K7, BNIP3L, RB1, and NEIL3, and gain of MYC, may lead to more aggressive prostate cancer in Black/African American men.

Dr. Choudhury on Future Research Directions for Pembrolizumab/Radium-223 in mCRPC

April 26th 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Apalutamide Maintains OS Benefit in Castration-Sensitive Prostate Cancer

April 26th 2021

Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.

Earlier Administration of Antiandrogens May Further Delay Disease Progression in Nonmetastatic CRPC

April 26th 2021

Natasha Garg, DO, discusses the impact of antiandrogens in the treatment of patients with nonmetastatic CRPC, shared advice for choosing among the available options, and projected what the future paradigm might look like.

One-Size-Fits-All Treatment Is Not Appropriate in Node-Positive Prostate Cancer

April 24th 2021

Jason Zhu, MD, discusses the need to tailor therapy with androgen-deprivation therapy, radiation, and antiandrogen agents for men with pathologic and clinical node-positive prostate cancer.

Dr. Ward on Considerations for Salvage Radiation Therapy in Prostate Cancer

April 23rd 2021

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Dr. Tewari on Key Differences Between Racial Subgroups in Prostate Cancer

April 23rd 2021

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Dr. Tewari on the Hallmarks of Cancer in Black Men With Prostate Cancer

April 22nd 2021

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Dr. Burgess on the FDA Accelerated Approval of Rucaparib in BRCA+ mCRPC

April 22nd 2021

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Dr. Tewari on the Potential Benefits of a Mobile MRI Unit in Prostate Cancer

April 21st 2021

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.

Dr. Ward on the Debate Over Adjuvant Radiation Therapy in Prostate Cancer

April 20th 2021

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

Regulatory Submissions for Apalutamide Combo in Metastatic CRPC Will Not Be Pursued

April 20th 2021

Regulatory submissions for the combination of apalutamide plus abiraterone acetate and prednisone in the treatment of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer will not be pursued.

Dr. Zhu on the Role of ADT in Pelvic Node–Positive Prostate Cancer

April 20th 2021

Jason Zhu, MD, discusses the role of androgen deprivation therapy in patients with pelvic node–positive prostate cancer.

Dr. Burgess on Treatment Considerations for PARP Inhibitors in Prostate Cancer

April 16th 2021

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

Nivolumab/Ipilimumab Showcases Significant Antitumor Activity in Metastatic CRPC

April 10th 2021

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Healthy Lifestyle May Reduce Likelihood of Lethal Prostate Cancer Among Those With High Genetic Risk

April 10th 2021

Maintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.

PARP Inhibitors Could Help Craft Better Personalized Medicine in Prostate Cancer

April 7th 2021

Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.